ARTICLE | Clinical News
PAN-301-1: Ph I started
February 1, 2017 9:44 PM UTC
Panacea began an open-label, dose-escalation, U.S. Phase I trial to evaluate intradermal PAN-301-1 in about 18 patients....
BCIQ Company Profiles
Panacea began an open-label, dose-escalation, U.S. Phase I trial to evaluate intradermal PAN-301-1 in about 18 patients....
BCIQ Company Profiles